New links between the human genome and inflammation tracers have been found by researchers in Finland. In a study of over ten million DNA variations, new possibilities for treatment of diseases such as multiple sclerosis, Crohn’s disease and celiac disease were uncovered.
Researchers at the Research Centre of Applied and Preventive Cardiovascular Medicine at the University of Turku, Finland noticed that the medicine daclizumab, previously used for treating organ rejection reactions, could possibly also be used in the treatment of multiple sclerosis and Crohn’s disease.
In addition, an increase in the activity of MIP1b-cytokine could also serve as a method of treatment against celiac disease and Behcet’s disease. Further clinical studies are required to confirm the observations.
Read More: New Inflammatory Marker Genome